Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy.
- Author:
Jun LIANG
1
;
Qing-fang LI
;
Ru-yong YAO
;
Hong-ying LÜ
;
Jian JIANG
;
Ying-ying SUN
;
Shan-ai SONG
;
Tao JIANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; genetics; pathology; Adenocarcinoma, Mucinous; drug therapy; genetics; pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; DNA-Binding Proteins; genetics; Disease Progression; Endonucleases; genetics; Female; Fluorouracil; administration & dosage; Follow-Up Studies; Glutathione S-Transferase pi; genetics; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; administration & dosage; Polymorphism, Genetic; Stomach Neoplasms; drug therapy; genetics; pathology; Survival Rate; X-ray Repair Cross Complementing Protein 1
- From: Chinese Journal of Oncology 2010;32(7):515-519
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the association between the polymorphisms of excision repair cross complementation group 1 (ERCC1), X-ray repair cross complementing 1 (XRCC1), glutathione S-transferase Pi 1 (GSTP1) and the survival of advanced gastric cancer patients treated with oxaliplatin-based combination chemotherapy.
METHODSEighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated. Peripheral venous blood was taken before chemotherapy. DNA was extracted from peripheral venous blood. The genetic polymorphisms were detected by real-time PCR assay. The association between time to progression, overall survival and the polymorphisms was analyzed.
RESULTSThe median time to progression of the 85 cases was 5.3 months, and the median overall survival was 8.0 months. ERCC1-118 C/C, XRCC1-399 G/G and GSTP1-105 A/G + G/G were favorable genotypes and the number of the favorable genotypes was associated with survival of the patients. The median overall survival was 12.5 months, 10.0 months, 6.5 months and 4.5 months for patients with 3 favorable genotypes, 2 favorable genotypes, 1 favorable genotype and none favorable genotype, respectively, with a significant difference (χ(2) = 35.54, P < 0.01).
CONCLUSIONGenetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with TTP and OS of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based combination chemotherapy as the first-line chemotherapy.
